The Medical Imaging & Technology Alliance (MITA) has submitted comments in response to the Centers for Medicare & Medicaid Services Proposed Decision Memorandum for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease.